Recently, another report revealed that acacetin (0.3–3 μM in vitro; 15 mg/kg in vivo) not only reduced ox-LDL-caused endothelial cell apoptosis by enhancing cellular antioxidant capacity through the methionine sulfoxide reductase A (MsrA)-Nrf2/Kelch-like ECH-associated protein 1 (Keap1) signaling axis in vitro but also markedly alleviated atherosclerosis by inhibiting oxidative stress and inflammation while promoting lipid metabolism in Western diet-fed ApoE−/− mice, which also suggested a potential therapeutic effect of acacetin on atherosclerosis-related CVD (Wu et al., 2021). The gene discussed is KEAP1; the disease is atherosclerosis.